178 related articles for article (PubMed ID: 20202962)
1. Risk factors for isoniazid hepatotoxicity in children with latent TB and TB: difference from adults.
Devrim I; Olukman O; Can D; Dizdarer C
Chest; 2010 Mar; 137(3):737-8. PubMed ID: 20202962
[No Abstract] [Full Text] [Related]
2. Isoniazid-induced hepatotoxicity in children with latent tuberculosis infection.
Devrim İ; Devrim F; Bayram N; Aktürk H; Aksay A; Can D; Apa H
Minerva Pediatr (Torino); 2021 Apr; 73(2):184-187. PubMed ID: 26377643
[TBL] [Abstract][Full Text] [Related]
3. Age-related risk of hepatotoxicity in the treatment of latent tuberculosis infection: a systematic review.
Kunst H; Khan KS
Int J Tuberc Lung Dis; 2010 Nov; 14(11):1374-81. PubMed ID: 20937175
[TBL] [Abstract][Full Text] [Related]
4. Isoniazid-induced acute liver failure during preventive therapy for latent tuberculosis infection.
Miyazawa S; Matsuoka S; Hamana S; Nagai S; Nakamura H; Nirei K; Moriyama M
Intern Med; 2015; 54(6):591-5. PubMed ID: 25786447
[TBL] [Abstract][Full Text] [Related]
5. Adherence to nine-month isoniazid for latent tuberculosis infection in healthcare workers: a prospective study in a tertiary hospital.
Chung SJ; Lee H; Koo GW; Min JH; Yeo Y; Park DW; Park TS; Moon JY; Kim SH; Kim TH; Sohn JW; Yoon HJ
Sci Rep; 2020 Apr; 10(1):6462. PubMed ID: 32296096
[TBL] [Abstract][Full Text] [Related]
6. Latent tuberculosis in childhood: tolerability of two different therapeutic approaches.
Tersigni C; Venturini E; Cordola C; Piccini P; Bianchi L; Montagnani C; Sollai S; Chiappini E; de Martino M; Galli L
Expert Rev Anti Infect Ther; 2018 Apr; 16(4):359-365. PubMed ID: 29465259
[TBL] [Abstract][Full Text] [Related]
7. Detection and management of latent tuberculosis in liver transplant patients.
Jafri SM; Singal AG; Kaul D; Fontana RJ
Liver Transpl; 2011 Mar; 17(3):306-14. PubMed ID: 21384513
[TBL] [Abstract][Full Text] [Related]
8. Severe isoniazid-associated liver injuries among persons being treated for latent tuberculosis infection - United States, 2004-2008.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2010 Mar; 59(8):224-9. PubMed ID: 20203555
[TBL] [Abstract][Full Text] [Related]
9. Baseline abnormal liver function tests are more important than age in the development of isoniazid-induced hepatoxicity for patients receiving preventive therapy for latent tuberculosis infection.
Gray EL; Goldberg HF
Intern Med J; 2016 Mar; 46(3):281-7. PubMed ID: 26648478
[TBL] [Abstract][Full Text] [Related]
10. Treatment of latent tuberculosis infection: a network meta-analysis.
Stagg HR; Zenner D; Harris RJ; Muñoz L; Lipman MC; Abubakar I
Ann Intern Med; 2014 Sep; 161(6):419-28. PubMed ID: 25111745
[TBL] [Abstract][Full Text] [Related]
11. Two-month regimen of isoniazid, rifampin and pirazinamid for latent tuberculosis infection.
Duarte R; Carvalho A; Correia A
Public Health; 2012 Sep; 126(9):760-2. PubMed ID: 22633080
[No Abstract] [Full Text] [Related]
12. First line anti-tuberculosis induced hepatotoxicity: incidence and risk factors.
Bouazzi OE; Hammi S; Bourkadi JE; Tebaa A; Tanani DS; Soulaymani-Bencheikh R; Badrane N; Bengueddour R
Pan Afr Med J; 2016; 25():167. PubMed ID: 28292129
[TBL] [Abstract][Full Text] [Related]
13. Benefit of treatment of latent tuberculosis infection in individual patients.
Dobler CC; Martin A; Marks GB
Eur Respir J; 2015 Nov; 46(5):1397-406. PubMed ID: 26405292
[TBL] [Abstract][Full Text] [Related]
14. Three months of weekly rifapentine plus isoniazid is less hepatotoxic than nine months of daily isoniazid for LTBI.
Bliven-Sizemore EE; Sterling TR; Shang N; Benator D; Schwartzman K; Reves R; Drobeniuc J; Bock N; Villarino ME;
Int J Tuberc Lung Dis; 2015 Sep; 19(9):1039-44, i-v. PubMed ID: 26260821
[TBL] [Abstract][Full Text] [Related]
15. [FREQUENCY AND RISK FACTORS OF SEVERE LIVER DYSFUNCTION IN ISONIAZID MONO-THERAPY FOR LATENT TUBERCULOSIS INFECTION].
Ito K
Kekkaku; 2016 Sep; 91(9):607-616. PubMed ID: 30646464
[TBL] [Abstract][Full Text] [Related]
16. The role of chronic hepatitis in isoniazid hepatotoxicity during treatment for latent tuberculosis infection.
Bliven EE; Podewils LJ
Int J Tuberc Lung Dis; 2009 Sep; 13(9):1054-60. PubMed ID: 19723392
[TBL] [Abstract][Full Text] [Related]
17. Tuberculosis: which drug regimen and when.
Hall J; Elliott C
J Fam Pract; 2015 Jan; 64(1):27-33. PubMed ID: 25574509
[TBL] [Abstract][Full Text] [Related]
18. Adverse effects and adherence to treatment of rifampicin 4 months vs isoniazid 6 months for latent tuberculosis: a retrospective analysis.
Fresard I; Bridevaux PO; Rochat T; Janssens JP
Swiss Med Wkly; 2011; 141():w13240. PubMed ID: 21842452
[TBL] [Abstract][Full Text] [Related]
19. Risk factors of isoniazid-induced hepatotoxicity in Tunisian tuberculosis patients.
Ben Fredj N; Gam R; Kerkni E; Chaabane A; Chadly Z; Boughattas N; Aouam K
Pharmacogenomics J; 2017 Jul; 17(4):372-377. PubMed ID: 27089936
[TBL] [Abstract][Full Text] [Related]
20. Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic.
Nolan CM; Goldberg SV; Buskin SE
JAMA; 1999 Mar; 281(11):1014-8. PubMed ID: 10086436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]